Spleen tyrosine kinase inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Spleen tyrosine kinase inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Spleen tyrosine kinase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Spleen tyrosine kinase inhibitors: Overview
Spleen tyrosine kinase (Syk) is a cytosolic non-receptor protein tyrosine kinase (PTK) and is mainly expressed in hematopoietic cells. Syk was recognized as a critical element in the B-cell receptor signaling pathway. Syk is also a key component in signal transduction from other immune receptors like Fc receptors and adhesion receptors. Syk inhibitors are a new group of small molecule inhibitors targeting BCR-mediated signaling pathways.
Syk was recognized as a critical element in the BCR signaling pathway. Syk is also a key component in signal transduction from other immune receptors like Fc receptors and adhesion receptors. Syk along with other BCR signaling molecules, Bruton tyrosine kinase (BTK), PI3K delta (PI3K?), and tumor necrosis factor (TNF) superfamily receptors was also found to be involved in signal transduction independent from the BCR. Syk is expressed primarily in hematopoietic cells like B-cells, monocytes, macrophages, mast cells, and neutrophils. Syk was recognized to be a potential target for the treatment of various hematologic cancers, autoimmune disorders, and other inflammatory states.
Report Highlights
This segment of the Spleen tyrosine kinase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Spleen tyrosine kinase inhibitors Emerging Drugs
Further product details are provided in the report……..
Spleen tyrosine kinase inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Spleen tyrosine kinase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
Spleen tyrosine kinase inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Spleen tyrosine kinase inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Spleen tyrosine kinase inhibitors drugs.
Spleen tyrosine kinase inhibitors Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Spleen tyrosine kinase inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Spleen tyrosine kinase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Spleen tyrosine kinase inhibitors: Overview
Spleen tyrosine kinase (Syk) is a cytosolic non-receptor protein tyrosine kinase (PTK) and is mainly expressed in hematopoietic cells. Syk was recognized as a critical element in the B-cell receptor signaling pathway. Syk is also a key component in signal transduction from other immune receptors like Fc receptors and adhesion receptors. Syk inhibitors are a new group of small molecule inhibitors targeting BCR-mediated signaling pathways.
Syk was recognized as a critical element in the BCR signaling pathway. Syk is also a key component in signal transduction from other immune receptors like Fc receptors and adhesion receptors. Syk along with other BCR signaling molecules, Bruton tyrosine kinase (BTK), PI3K delta (PI3K?), and tumor necrosis factor (TNF) superfamily receptors was also found to be involved in signal transduction independent from the BCR. Syk is expressed primarily in hematopoietic cells like B-cells, monocytes, macrophages, mast cells, and neutrophils. Syk was recognized to be a potential target for the treatment of various hematologic cancers, autoimmune disorders, and other inflammatory states.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Spleen tyrosine kinase inhibitors R&D. The therapies under development are focused on novel approaches for Spleen tyrosine kinase inhibitors.
This segment of the Spleen tyrosine kinase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Spleen tyrosine kinase inhibitors Emerging Drugs
- Fostamatinib: Rigel Pharmaceuticals
- Entospletinib: Kronos Bio
Further product details are provided in the report……..
Spleen tyrosine kinase inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Spleen tyrosine kinase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Spleen tyrosine kinase inhibitors
- Phases
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Spleen tyrosine kinase inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Spleen tyrosine kinase inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Spleen tyrosine kinase inhibitors drugs.
Spleen tyrosine kinase inhibitors Report Insights
- Spleen tyrosine kinase inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Spleen tyrosine kinase inhibitors drugs?
- How many Spleen tyrosine kinase inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Spleen tyrosine kinase inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Spleen tyrosine kinase inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Spleen tyrosine kinase inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- Dermavant Sciences
- Rigel Pharmaceuticals
- Kronos Bio
- Hutchison MediPharma
- Hanmi Pharmaceutical
- Genosco
- Asana BioSciences
- Cerdulatinib
- Fostamatinib
- Entospletinib
- Lanraplenib
- HMPL-523
- HM43239
- SKI O 703
- ASN002
Introduction
Executive Summary
Spleen tyrosine kinase inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Fostamatinib: Rigel Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Entospletinib: Kronos Bio
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
HM43239: Hanmi Pharmaceutical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Spleen tyrosine kinase inhibitors Key Companies
Spleen tyrosine kinase inhibitors Key Products
Spleen tyrosine kinase inhibitors- Unmet Needs
Spleen tyrosine kinase inhibitors- Market Drivers and Barriers
Spleen tyrosine kinase inhibitors- Future Perspectives and Conclusion
Spleen tyrosine kinase inhibitors Analyst Views
Spleen tyrosine kinase inhibitors Key Companies
Appendix
Executive Summary
Spleen tyrosine kinase inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Fostamatinib: Rigel Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Entospletinib: Kronos Bio
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
HM43239: Hanmi Pharmaceutical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Spleen tyrosine kinase inhibitors Key Companies
Spleen tyrosine kinase inhibitors Key Products
Spleen tyrosine kinase inhibitors- Unmet Needs
Spleen tyrosine kinase inhibitors- Market Drivers and Barriers
Spleen tyrosine kinase inhibitors- Future Perspectives and Conclusion
Spleen tyrosine kinase inhibitors Analyst Views
Spleen tyrosine kinase inhibitors Key Companies
Appendix